News

Vera Therapeutics Announces Upcoming Webcast on ORIGIN 3 Trial

Vera Therapeutics Announces Upcoming Webcast on ORIGIN 3 Trial

Investor Call and Webcast Announcement

BRISBANE, Calif. — Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology firm devoted to innovative treatments for serious immunological diseases, has announced a forthcoming investor call and webcast scheduled for November 6, 2025, at 4:30 PM ET. This event will spotlight the preliminary outcomes from the ORIGIN Phase 3 clinical trial of atacicept, aimed at treating IgA nephropathy (IgAN), which will be showcased at a primary session during an eminent medical conference. The company invites participants to review the significant findings that reflect their commitment to advancing patient care.

What to Expect During the Webcast

The presentation will feature insights from esteemed experts such as Dr. Jonathan Barratt, a leading figure in renal medicine at the University of Leicester, and Dr. Richard Lafayette of Stanford University, who bring extensive knowledge and experience in nephrology. Following the detailed presentation, a live question-and-answer segment will allow investors to engage directly with the speakers, enhancing the overall transparency and accessibility of the information shared.

About Dr. Jonathan Barratt

Dr. Barratt specializes in IgAN and leads a prominent research group within the University of Leicester’s College of Life Sciences. With a strong focus on translating research into effective treatments, his work includes leading numerous international clinical trials aimed at finding improvement strategies for this debilitating condition. Dr. Barratt also contributes to multiple organizations, actively collaborating with pharmaceutical companies to enhance treatment methodologies.

About Dr. Richard Lafayette

As Director of the Stanford Glomerular Disease Center, Dr. Lafayette is renowned for his profound understanding of nephrology and glomerular diseases. His distinguished career encompasses substantial educational efforts and board memberships in leading nephrology communities, alongside significant contributions to various clinical trials and research projects focused on enhancing patient outcomes in kidney health.

Insights into Atacicept

Atacicept is an investigational fusion protein designed to inhibit BAFF and APRIL, cytokines crucial in the regulation of B-cell survival. Elevated levels of these cytokines are often associated with the progression of conditions like IgAN and lupus nephritis, making atacicept a promising candidate in kidney disease management. This therapy showcases the potential for innovation in tackling complex immunological disorders.

Get Updates on the ORIGIN Clinical Program

The ORIGIN Phase 2b study has produced encouraging results, achieving both primary and secondary endpoints. Participants demonstrated significant reductions in proteinuria and stabilization of kidney function. Safety assessments revealed a comparable profile between atacicept and placebo, contributing to a robust basis for ongoing clinical development. This success positions Vera Therapeutics as a leader in the evolving landscape of immunological therapies.

Future Directions for Atacicept

Atacicept's designation as a Breakthrough Therapy by the FDA underlines its potential to outperform existing treatment options for IgAN. The ORIGIN trial's results indicate that Vera Therapeutics not only leads in research but also embodies a transformative approach in patient care by ensuring that innovative treatments reach those in need. The company is actively exploring the long-term effectiveness of atacicept through the ORIGIN Extend study, providing participants with continued access to the treatment.

About Vera Therapeutics

Vera Therapeutics is dedicated to revolutionizing care for patients with immunological diseases through groundbreaking therapies. Its flagship product, atacicept, is designed to address the underlying causes of diseases like IgAN. As the company explores additional areas where reducing autoantibodies can have significant benefits, it continues to uphold its mission of transforming standards of care and expanding its development pipeline with innovative treatments like VT-109 and MAU868.

Frequently Asked Questions

What is the focus of Vera Therapeutics?

Vera Therapeutics primarily focuses on developing innovative treatments for serious immunological conditions, aiming to improve patient outcomes significantly.

What is the ORIGIN trial about?

The ORIGIN trial investigates the efficacy of atacicept in treating IgA nephropathy, aiming to assess its impact on kidney function and related symptoms.

Who are the experts participating in the upcoming webcast?

Dr. Jonathan Barratt and Dr. Richard Lafayette, both renowned nephrologists, will participate in the webcast to provide insights into the ORIGIN trial outcomes.

What is atacicept?

Atacicept is a novel investigational drug aimed at reducing the activity of specific cytokines involved in autoimmune diseases, particularly focusing on IgAN and lupus nephritis.

How can I stay updated on Vera Therapeutics’ developments?

Interested individuals can frequently check the Vera Therapeutics official website for updates on clinical trials, new studies, and additional company news.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 13

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 131

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

D.Law's New Office: A Major Step Forward in Growth

Updated Category News Views 158

D.Law Opens New Office in Glendale D.Law is excited to announce a significant milestone in its expansion with the launch of its new office at 450 N. Brand Blvd, Suite 840. This important development represents more than just a new location; it embodies the firm's dedication to growing its capabilities and providing better service to its clients. A New Beginning for D.Law...

Continue Reading
Innovative Hunting Shack Designed for Comfort and Covert Use

Updated Category News Views 155

Revolutionizing the Hunting Experience Hunting requires a blend of stealth, comfort, and practicality, all of which have inspired an exciting innovation: the specially designed hunting shack. An inventor focused on optimizing the hunting experience has created this remarkable mobile structure, ideal for outdoor enthusiasts seeking to enhance their hunting adventures. A...

Continue Reading
ALTA Honors Senate for Confirming Pulte as FHFA Director

Updated Category News Views 236

ALTA Celebrates Senate Confirmation of Bill Pulte The American Land Title Association (ALTA) has expressed its appreciation to the U.S. Senate following the confirmation of Bill Pulte as the new director of the Federal Housing Finance Agency (FHFA). This announcement marks a significant moment for both ALTA and the housing industry. Bill Pulte’s Role at FHFA Bill Pulte,...

Continue Reading
Celebrating Talar Guedikian's Achievement as Paralegal of the Year

Updated Category News Views 181

Talar Guedikian Named 2025 AAJ Paralegal of the Year The legal community is buzzing with excitement as Talar Guedikian, a dedicated Senior Litigation Paralegal, has been honored with the prestigious title of the 2025 AAJ Paralegal of the Year. This recognition, sponsored by Advocate Capital, showcases her exceptional capabilities and unwavering commitment to the legal...

Continue Reading
Bauer Hockey Welcomes Gillian Meek as New Executive Leader

Updated Category News Views 237

Bauer Hockey Appoints Gillian Meek as Executive Vice President Bauer Hockey, recognized globally as the leading manufacturer of hockey equipment and the premier brand within the sport, has made a significant executive change. The company has welcomed Gillian Meek as its new Executive Vice President and General Manager. This strategic move was announced recently, and it...

Continue Reading